Identification of Predictive Biomarkers Based on Cytokine Profiles for Molecular Relapse After Treatment-Free Remission in Chronic Myeloid Leukemia Patients
Cells · 27.04.2026 · 15 (9) · 791
DOI: 10.3390/cells15090791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 27.04.2026. Verfasst von Bianca Vasconcelos Cordoba und 33 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigaciones Oncológicas-Fundación Cáncer (CIO-FUCA), Buenos Aires 1426, Argentina. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Cytokines, Biomarkers, Tumor. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT), Fundación SALES, Fundación Cáncer (FUCA).
Abstract (Originalsprache)
Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) into a manageable disease, and discontinuation has become a feasible goal for many patients. However, molecular relapse after TKI cessation remains a challenge. This study investigated factors influencing molecular relapse-free survival (MRFS) in a real-world cohort of CML patients undergoing TKI discontinuation, focusing on clinical, molecular, and immune-related variables. Traditional prognostic tools, such as the Sokal score, showed limited capacity to predict relapse risk in this context. Instead, total treatment duration and depth of molecular response emerged as critical predictors, with longer therapy and deeper remission associated with improved outcomes. A key novel finding was the prognostic relevance of cytokine profiles, particularly interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1). These cytokines were strong predictors of relapse in a decision tree model that achieved high specificity and positive predictive value in an independent validation cohort. Notably, lower IL-6 and MCP-1 levels were associated with increased relapse risk, suggesting reduced immune surveillance may contribute to recurrence. Integrating cytokine signatures with molecular markers improved prognostic accuracy, supporting immune biomarkers as complements to established clinical parameters. These findings underscore the complexity of relapse mechanisms and the need for individualized risk assessment when considering TKI discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Investigaciones Oncológicas-Fundación Cáncer (CIO-FUCA), Buenos Aires 1426, Argentina.
- Fundación para Combatir la Leucemia (FUNDALEU), Buenos Aires 1114, Argentina.
- Hospital José María Ramos Mejía, Buenos Aires 1221, Argentina.
- Hospital Italiano, Buenos Aires 1199, Argentina.
- Hospital Británico, Buenos Aires 1280, Argentina.
- Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Buenos Aires 1425, Argentina.
ORCID-Profile: Bianca Vasconcelos Cordoba, Georgina Emilia Bendek Del Prete, Romina Mariano, Estrella Mariel Levy
Förderung
- Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT)
- Fundación SALES
- Fundación Cáncer (FUCA)
- Fundación Pedro Mosoteguy
- FUNDALEU
- Novartis Argentina
- CONICET doctoral fellowship
Zitieren
APA
Vasconcelos Cordoba, B., Pavlovsky, C., Sanchez, M. B., Moiraghi, E. B., Varela, A. I., Pavlovsky, M. A., Giere, I. A., Freilich, F. F., Fernandez, I., Mela Osório, M. J., Tannuri, R. K., Sackmann, F., Juni, M., Bendek Del Prete, G. E., Bullorsky, E. O., Dupont, J., Freitas, J., Ventriglia, V., Labanca, A. G., …, & Bianchini, M. (2026). Identification of Predictive Biomarkers Based on Cytokine Profiles for Molecular Relapse After Treatment-Free Remission in Chronic Myeloid Leukemia Patients. Cells, 15(9), 791. https://doi.org/10.3390/cells15090791
Vancouver
Vasconcelos Cordoba B, Pavlovsky C, Sanchez MB, Moiraghi EB, Varela AI, Pavlovsky MA, et al. Identification of Predictive Biomarkers Based on Cytokine Profiles for Molecular Relapse After Treatment-Free Remission in Chronic Myeloid Leukemia Patients. Cells. 2026;15(9):791. doi:10.3390/cells15090791
BibTeX
@article{VasconcelosCordoba2026,
author = {Vasconcelos Cordoba, Bianca and Pavlovsky, Carolina and Sanchez, María Belén and Moiraghi, Elena Beatriz and Varela, Ana Ines and Pavlovsky, Miguel Arturo and Giere, Isabel Amanda and Freilich, Franco Federico and Fernandez, Isolda and Mela Osório, Maria José and Tannuri, Ricardo Khalil and Sackmann, Federico and Juni, Mariana and Bendek Del Prete, Georgina Emilia and Bullorsky, Eduardo Oscar and Dupont, Juan and Freitas, Josefina and Ventriglia, Verónica and Labanca, Ana Garcia and Mariano, Romina and Gumpel, Carina and Macchiavello, Etelvina and Aranguren, Pedro Negri and Paoletti, Mariano and Rojas, Francisca and Tosin, Maria Fernanda and Catalan, Marta and Custidiano, Maria Del Rosario and Foncuberta, Maria Cecilia and Sánchez Ávalos, Julio Cesar and Miranda, Silvia and Mordoh, José and Levy, Estrella Mariel and Bianchini, Michele},
title = {Identification of Predictive Biomarkers Based on Cytokine Profiles for Molecular Relapse After Treatment-Free Remission in Chronic Myeloid Leukemia Patients},
journal = {Cells},
year = {2026},
volume = {15},
number = {9},
pages = {791},
doi = {10.3390/cells15090791}
}
EUVIMED